MM Romero-Ruiz, M Romero-Serrano, A Serrano-González, MÁ Serrera-Figallo, JL Gutiérrez-Pérez, D Torres-Lagares. Proposal for a preventive protocol for medication-related osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2021 May 1;26 (3):e314-26.
doi:10.4317/medoral.24197
https://dx.doi.org/doi:10.4317/medoral.24197
1. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiodt M, Klinge B. The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res. 2018;29:54-92. |
PMid:30306695 |
2. Ruggiero SL, Dodson TB, Fantasia J, Aghaloo T, Mehrotra B, Felice O. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw -2014 update-. J Oral Maxillofac Surg. 2014;72:1938-56. |
PMid:25234529 |
3. Aghaloo TL, Kang B, Sung EC, Shoff M, Ronconi M, Gotcher JE, et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res. 2011;26:1871-82. |
PMid:21351151 PMCid:PMC3596511 |
4. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and associations with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181-8. |
PMid:20361252 |
5. Yamazaki T, Yamori M, Ishizaki T, Asaki K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012;41:1307-403. |
PMid:22840716 |
6. Saad F, Brown J, Van Poznack C, Ibrahim T, Stemmer S, Stopeck A, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341-7. |
PMid:21986094 |
7. Katsarelis H, Shah N, Dharival D, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res. 2015;94:534-9. |
PMid:25710950 |
8. Belibasakis G, Bostanci N, Hashim A, Johansson A, Aduse J, Curtis M, et al. Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. Microb Pathog. 2007;43:46-53. |
PMid:17448630 |
9. Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, et al. Bisphosphonate related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?. J Oral Maxillofac Surg. 2010;68:1158-61. |
PMid:20138420 |
10. Saad F, Brown J, van Poznak C, Ibraim T, Stemmer S, Stopeck A, et al. Incidence risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341-7. |
PMid:21986094 |
11. Ata-Ali J, Ata-Ali F, Peñarrocha D, Galindo P. What is the impact of bisphosphonates therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res. 2016;27:e38-46. |
PMid:25406770 |
12. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schidt M, Kingle B. The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res. 2018;29:54-92. |
PMid:30306695 |
13. Giovannacci I, Meleti M, Manfredi M, Mortellaro C, Greco A, Bonanini M, et al. Medication related osteonecrosis of the jaw around dental implants: implant surgery-triggered or implant presence-triggered osteonecrosis?. J Craniofac Surg. 2016;27:e697-701. |
PMid:27092912 |
14. Fernández A, Herion F, Rompen E, Reginster J, Magremanne M, Lambert F. Dramatic osteonecrosis of the jaw associated with oral bisphosphonates periodontitis, and dental implant removal. J Clin Periodontol. 2015;42:e190-5. |
PMid:25327450 |
15. Holzinger D, Seeman R, Matoni N, Ewers R, Millesi W, Wutzl A. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2014;72:e1931-8. |
PMid:25234534 |
16. Lazarovici T, Yahalom R, Taicher S, Schwartz D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg. 2010;68:e790-6. |
PMid:20307764 |
17. Escobedo M, Cobo J, Junquera S, Olay S, Junquera LM. Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis; case series and literature review. J Stomatol Oral Maxillofac Surg. 2020;121:40-8. |
PMid:31035023 |
18. Walter C, Al-Navas B, Wolff T, Schiegnitz E, Grotz K. Dental implants in patients treated with antirresorptive medication- a systematic literature review. Int J Implant Dent. 2016;2:9-15. |
PMid:27747701 PMCid:PMC5005701 |
19. Bermúdez E, Serrera MA, Gutiérrez A, Romero MM, Castillo R, Gutiérrez JL, et al. Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. Med Oral Patol Oral Cir Bucal. 2017;22:e43-57. |
PMid:27918742 |
20. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-20. |
PMid:18689864 |
21. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonates-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc. 2011;77:b147. |
PMid:22129778 |
22. Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff KC, Canallatos P, et al. Osteonecrosis of the jaw- prevention and treatment strategies for oral health professionals. Oral Oncol. 2013;49:878-89. |
PMid:23890929 |
23. Regev E, Lustmann J, Nashef R. Atraumatic teeth extraction in bisphosphonate-treated patients. J Oral Maxillofac Surg. 2008;66:1157-61. |
PMid:18486780 |
24. Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010;68:797- 804. |
PMid:20307765 |
25. Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009;20:137-45. |
PMid:18647964 |
26. Lodi G, Sardella A, Salis A, Demarose F, Tarozzi M, Carassi A. Tooth extraction in patients taking intravenous bisphosphonates: A preventive protocol and cases series. J Oral Maxillofac Surg. 2010;68:107-10. |
PMid:20006163 |
27. Ferlito S, Puzzo S, Liardo C. Preventive protocol for tooth extractions in patients treated with Zoledronate: A case series. J Oral Maxillofac Surg. 2011;69:e1-4. |
PMid:21316136 |
28. Kwon TG, Lee CO, Park JW, Choi SY, Rijal G, Shin HI. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2014;25:e632-40. |
PMid:23278625 |
29. Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol. 2012;23:193-200. |
PMid:21427065 |
30. Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab. 2015;33:119-24. |
PMid:24553860 |
31. Troeltzsch M, Cagna D, Stahler P, Probst F, Kaeppler G, Troeltzsch M, et al. Clinical features of peri-implant medication-related osteonecrosis of the jaw: is there an association to peri-implantitis? J Craniomaxillofac Surg. 2016;44:1945-51. |
PMid:27836551 |
32. Mücke T, Keppe H, Hein J, Wolf K, Mitchell D, Kesting M, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. J Cranio Maxillofac Surg. 2016;44:1689-93. |
PMid:27555374 |
33. Otto S, Pautke C, Vanden Wyngaert T, Niepel D, Schiodt M. Medication related osteonecrosis of the jaw: prevention diagnosis and management in patients with cancer bone metastases. Cancer Treat Rew. 2018;69:177-87. |
PMid:30055439 |
34. Diniz-Freitas M, Limeres J. Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e250-9. |
PMid:26827065 PMCid:PMC4788807 |
35. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432. |
PMid:28983908 PMCid:PMC6485859 |
36. Di Fede O, Panzarella, Maureci R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018;2018:2684924. |
PMid:30306086 PMCid:PMC6164200 |
37. Karna H, González J, Radia H, Sedghizadeh P, Enciso R. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses. Oral Oncol. 2018;85:15-23. |
PMid:30220314 |
38. De Freitas NR, Lima LB, de Moura MB, Veloso CC, Simamoto PC, de Magalhães D. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e644-51. |
PMid:27475681 PMCid:PMC5005105 |
39. Guazo R, Sbricoli L, Sara R, Bressan E, Piattelli A, Laculli F. Medication related osteonecrosis of the jaw and dental implants failures; a systematic review. J Oral Implant. 2017;43:51-7. |
PMid:28231038 |
40. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2012;8:90-6. |
PMid:22124271 |